Research Highlights Expanded Clinical Uses of SGLT2 Inhibitors Medha Baranwal6 Jan 2025 8:30 AM ISTUSA: A recent editorial published in the Journal of Cardiothoracic and Vascular Anesthesia highlights the growing clinical applications of...
Ertugliflozin Promising in Reducing Liver Fat and Complications in NAFLD Patients with Type 2 Diabetes: Study Medha Baranwal29 Nov 2024 9:00 AM ISTPakistan: A recent randomized controlled trial has highlighted the potential of ertugliflozin in improving liver health in patients with nonalcoholic...
Ertugliflozin Lowers Uric Acid and Reduces Gout Risk in Type 2 Diabetes Patients with CVD, VERTIS CV Analysis Medha Baranwal24 Sept 2024 9:00 AM ISTCanada: Recent post hoc analyses from the VERTIS CV trial reveal promising results for ertugliflozin, a medication used to manage type 2 diabetes. The...
Ertugliflozin Significantly Reduces Functional Mitral Regurgitation in Heart Failure patients : Study Dr Riya Dave9 May 2024 10:15 AM ISTResearchers have found that ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, significantly improves left ventricular global...
SGLT2 inhibitor ertugliflozin fails to prevent HF hospitalization at EF>60 percent: VERTIS CV analyses Medha Baranwal27 Oct 2023 12:30 PM ISTUSA: Post-hoc analyses of the VERTIS CV trial failed to show the ability of SGLT2 inhibitor ertugliflozin (Steglatro) to reduce hospitalization for...
Ertugliflozin Shows Better Renal Outcomes in diabetes patients with atherosclerotic CVD MD Bureau20 March 2021 12:03 AM ISTErtugliflozin is a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), is an approved glucose-lowering therapy in type 2 diabetes mellitus....
NEJM study confirms cardiac safety of Ertugliflozin in diabetes Dr Satabdi Saha25 Sept 2020 3:15 PM ISTAmong patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was non-inferior to placebo concerning major adverse...
Ertugliflozin safe bet to lower blood sugar, BP and weight in elderly diabetics: Study Medha Baranwal6 Aug 2020 12:00 PM ISTUSA: The use of ertugliflozin can improve blood sugar, blood pressure, and body weight in both younger and older patients with type 2 diabetes (T2D),...
Ertugliflozin reduces hospitalization risk due to heart failure in diabetes Medha Baranwal25 Jun 2020 10:45 AM ISTDelhi: SGTL2 inhibitor ertugliflozin reduces heart failure hospitalization risk but does not confer a cardiovascular mortality benefit in...
Ertugliflozin protects kidneys while lowering blood sugar in diabetes Dr. Kamal Kant Kohli2 Jun 2020 12:15 PM ISTSodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with protective renal and cardiovascular effects in addition to lowering blood sugar...
